Sinovac Biotech

SVA · NASDAQ

$6.47−$0.02 (−0.31%)TodayMarket closed · Feb 22, 3:00 PM ET

No price history for this range.

Latest news

NewsAug 17, 8:18 AM ET
Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY
Press releaseAug 17, 8:00 AM ETBusiness Wire
SINOVAC Reports Unaudited First Half of 2026 Financial Results
Press releaseJul 15, 2:00 AM ETBusiness Wire
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Press releaseJun 15, 6:00 AM ETBusiness Wire
SINOVAC Regained Compliance With the Nasdaq Global Market's Listing Requirements
Press releaseJun 5, 4:01 PM ETBusiness Wire
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
Press releaseMay 29, 4:01 PM ETBusiness Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
Press releaseMay 21, 6:30 AM ETBusiness Wire
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
NewsMay 8, 5:08 PM ET
Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY
Press releaseMay 8, 5:00 PM ETBusiness Wire
SINOVAC Reports Unaudited First Half of 2025 Financial Results
Press releaseApr 30, 9:22 AM ETBusiness Wire
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Press releaseJan 22, 6:00 AM ETBusiness Wire
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Press releaseJan 4, 10:13 AM ETBusiness Wire
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
Press releaseJan 4, 10:00 AM ETBusiness Wire
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Press releaseDec 17, 7:00 AM ETBusiness Wire
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
Press releaseNov 18, 3:00 PM ETBusiness Wire
SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Press releaseNov 11, 5:00 PM ETPRNewswire
/C O R R E C T I O N -- Heng Ren Partners/
Press releaseNov 11, 5:00 PM ETPRNewswire
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
Press releaseOct 24, 10:30 AM ETBusiness Wire
SINOVAC Announces Appointment of Independent Auditor
Press releaseJul 11, 4:21 PM ETBusiness Wire
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
Press releaseJul 10, 7:23 AM ETBusiness Wire
Newly Elected Directors of Sinovac Hold the First Board Meeting
Press releaseJul 9, 12:34 PM ETBusiness Wire
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
Press releaseJul 9, 12:27 PM ETBusiness Wire
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
Press releaseJul 9, 1:39 AM ETBusiness Wire
SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares
Press releaseJul 9, 1:17 AM ETBusiness Wire
Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting
Press releaseJul 9, 1:05 AM ETBusiness Wire
Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote
Press releaseJul 7, 3:26 PM ETBusiness Wire
Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2
Press releaseJul 7, 1:46 AM ETBusiness Wire
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
Press releaseJul 3, 7:34 PM ETBusiness Wire
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
Press releaseJul 2, 10:55 AM ETBusiness Wire
United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac
Press releaseJul 2, 9:20 AM ETBusiness Wire
SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
Press releaseJul 2, 1:03 AM ETBusiness Wire
Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place
Press releaseJun 16, 11:52 AM ETBusiness Wire
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
Press releaseJun 12, 7:04 PM ETBusiness Wire
SINOVAC's Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders
Press releaseJun 11, 8:30 AM ETBusiness Wire
Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims
Press releaseApr 23, 9:00 PM ETBusiness Wire
Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board's Value Destructive Actions
Press releaseApr 10, 3:44 PM ETPRNewswire
Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share
Press releaseAug 16, 8:54 AM ETBusiness Wire
SINOVAC Reports Unaudited First Half of 2024 Financial Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY

SINOVAC Reports Unaudited First Half of 2026 Financial Results

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

SINOVAC Regained Compliance With the Nasdaq Global Market's Listing Requirements

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY

SINOVAC Reports Unaudited First Half of 2025 Financial Results

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

/C O R R E C T I O N -- Heng Ren Partners/

Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

SINOVAC Announces Appointment of Independent Auditor

SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

Newly Elected Directors of Sinovac Hold the First Board Meeting

SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board

SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares

Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting

Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2

Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac

SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place

SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board

SINOVAC's Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders

Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims

Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board's Value Destructive Actions

Heng Ren Partners Calls on Sinovac to Disclose the Record and Payment Dates of the Special Dividend and Distribute an Additional Dividend of $41 per Share

SINOVAC Reports Unaudited First Half of 2024 Financial Results